Buy DYAI by Sep 14, 2026.

I've been digging into Dyadic International (**NASDAQ: DYAI)** and think it deserves a closer look from investors interested in biotech infrastructure rather than traditional drug-development companies. What caught my attention is that **DYAI** isn't developing a single drug and hoping for FDA approval. Instead, they're building a manufacturing platform (the C1 protein production technology) that could potentially help companies produce biologics, vaccines, antibodies, enzymes, and recombinant proteins faster and at a lower cost. A few things stood out: • Platform …